Allworth Financial’s Heron Therapeutics HRTX Stock Holding History

Allworth Financial’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.12K	Buy	14,341 +4,818	+51%	+$3.86K	﹤0.01%	4004
2026 Q1	$7.62K	Buy	9,523 +194	+2%	+$225	﹤0.01%	3687
2025 Q4	$12.1K	Buy	9,329 +7,775	+500%	+$9.6K	﹤0.01%	3139
2025 Q3	$1.96K	Buy	1,554 +1,519	+4,340%	+$2.41K	﹤0.01%	4012
2025 Q2	$73	Buy	+35	New	+$71	﹤0.01%	4416
2024 Q4	–	Sell	-301	Closed	-$599	–	3994
2024 Q3	$599	Hold	301	–	–	﹤0.01%	3372
2024 Q2	$979	Hold	301	–	–	﹤0.01%	3169
2024 Q1	$834	Hold	301	–	–	﹤0.01%	3138
2023 Q4	$512	Buy	+301	New	+$331	﹤0.01%	3126
2021 Q4	–	Sell	-150	Closed	-$2K	–	2023
2021 Q3	$2K	Hold	150	–	–	﹤0.01%	1681
2021 Q2	$2K	Hold	150	–	–	﹤0.01%	1373
2021 Q1	$2K	Hold	150	–	–	﹤0.01%	1305
2020 Q4	$3K	Buy	+150	New	+$2.61K	﹤0.01%	1079

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Allworth Financial's HRTX Position: Q2 2026 in Review

Allworth Financial increased its Heron Therapeutics (HRTX) stake by 51% in Q2 2026, buying an estimated $3.86K and bringing the position to 14,341 shares worth $6.12K. The position accounts for ﹤0.01% of the portfolio, ranked #4004.

Allworth Financial first reported a position in HRTX in Q4 2020 and has held it in 13 quarters since. The position peaked at $12.1K in Q4 2025. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

Allworth Financial held 14,341 shares of Heron Therapeutics worth $6.12K as of Q2 2026.
Allworth Financial bought 4,818 Heron Therapeutics shares in Q2 2026, an estimated $3.86K.
Heron Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #4004 holding.
Allworth Financial first reported a position in Heron Therapeutics in Q4 2020 and has held it in 13 quarters since.
Allworth Financial's Heron Therapeutics position peaked at $12.1K in Q4 2025.
163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.